Back to Dashboard







Gilead Sciences, Inc. (GILD)
Real-time intraday values
Market Overview
From:
To:
GILD Intraday
No data available
SymbolGILD
IPO DateJan 22, 1992
CEOMr. Daniel Patrick O'Day
Full Time Employees17k
SectorHealthcare
IndustryDrug Manufacturers - General
CountryUnited States
ExchangeNasdaqGS
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus, a T-cell therapy for the treatment of adult patients; Trodelvy, an injection for intravenous use; and Yescarta, a suspension for intravenous infusion, is a CAR T-cell therapy for the treatment of adult patients. Further, it provides AmBisome, for the treatment of serious invasive fungal infections; and Veklury for the treatment of COVID-19. Additionally, the company engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company has collaboration agreements with Shenzhen Pregene Biopharma Co., Ltd.; Abingworth; Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company has a partnership with Pan American Health Organization (PAHO) to accelerate access to lenacapavir for HIV prevention as pre-exposure prophylaxis (PrEP) across all PAHO member states in Latin America and the Caribbean. The company was incorporated in 1987 and is headquartered in Foster City, California.
Performance
| Period | Return % | Value Change |
|---|---|---|
| 1 Day | -0.06% | -0.10 US$ |
| 5 Days | -0.98% | -1.65 US$ |
| 1 Month | +8.37% | +12.86 US$ |
| 6 Months | +23.87% | +32.07 US$ |
Analyzing Market with AI
Evaluating the last 30 days of history and fundamental metrics of GILD...
Key Statistics
Market Cap
206.43B
P/E Ratio
N/A
Div Yield
1.97%
52W High
$176.58
52W Low
$116.88
Analyst Consensus
ConsensusBuy
Bullish2177.8%
Neutral518.5%
Bearish13.7%
52W Analyst Price Targets
Min Target
$131.00
$131.00
Max Target
$200.00
$200.00
Current$166.43
Avg Target$175.92
Analyst Recommendations
Target Price:$175.92($131.00 - $200.00)
Looking for more stocks? Explore them in the screener
Community Thoughts
Share your analysis and sentiment on GILD
Join the community to share your analysis
Latest News for GILD

HIV Clinical Trials - Global Strategic Business Report 2026-2032 Featuring Strategic Intelligence on Gilead, ViiV Healthcare, Merck, and Pfizer
GlobeNewswire•Nov 20, 2026, 03:19 PM
Mizuho Securities Adjusts Gilead Sciences Price Target to $182 From $170, Maintains Outperform Rating
MT Newswires•Nov 20, 2026, 03:00 PM

Is It Too Early To Buy Insmed Stock?
Trefis•Nov 20, 2026, 02:29 PM

How Investors Are Reacting To Gilead Sciences (GILD) HIV Prevention Expansion
Simply Wall St.•Nov 19, 2026, 01:12 PM

Should You Buy Exelixis Stock For Its Cash?
Trefis•Nov 19, 2026, 11:43 AM

Where Could Gilead's Next Growth Come From?
Trefis•Nov 19, 2026, 11:43 AM
How Many Shares of Bristol Myers Squibb, Merck or Gilead Sciences Pay $1,000 a Month in Dividends?
TIKR•Nov 18, 2026, 03:49 PM

Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know
Zacks•Nov 18, 2026, 01:00 PM
iShares Biotechnology ETF (IBB) Buys $16.2 Million More Gilead on Nov. 16
GuruFocus.com•Nov 18, 2026, 11:05 AM
Gilead Sciences Insider Sold Shares Worth $4,775,527, According to a Recent SEC Filing
MT Newswires•Nov 18, 2026, 08:29 AM